PRTK - Paratek Pharmaceuticals GAAP EPS of -$0.13 misses by $0.23 revenue of $75.6M beats by $12.13M

2023-03-16 14:42:30 ET

• Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q4 GAAP EPS of -$0.13 misses by $0.23 .
• Revenue of $75.6M (+137.7% Y/Y) beats by $12.13M .
• Shares -26% .

• Paratek also announced its full-year 2023 revenue guidance, which is expected to be in the range of $143.0 to $158.0 million, which includes the following components:

  • NUZYRA net U.S. sales of approximately $125.0 to $135.0 million.
  • BARDA government contract service and grant revenue between $15.0 to $20.0 million.
  • Royalty and collaboration revenue of approximately $3.0 million.

  Paratek expects to reduce full-year 2023 R&D and SG&A expense below that incurred in 2022.

For further details see: